Get the Stockscreener App
33.76
3.46%
-1.21
After Hours:
33.15
-0.61
-1.81%
Tg Therapeutics Inc stock is traded at $33.76, with a volume of 2.07M.
It is down -3.46% in the last 24 hours and up +6.08% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$34.97
Open:
$34.86
24h Volume:
2.07M
Relative Volume:
0.96
Market Cap:
$5.36B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-306.91
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-8.02%
1M Performance:
+6.08%
6M Performance:
-6.17%
1Y Performance:
+54.65%
1-Day Range:
$33.10
$35.01
1-Week Range:
$33.10
$37.45
52-Week Range:
$21.65
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.76 | 5.55B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
How risky is TG Therapeutics Inc. (NKB2) stock compared to peers2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Is TG Therapeutics Inc. stock bottoming outJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Market reaction to TG Therapeutics Inc.’s recent newsMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
What makes TG Therapeutics Inc. (NKB2) stock appealing to growth investorsMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Is TG Therapeutics Inc. still worth holding after the dipJuly 2025 Retail & Verified Chart Pattern Trade Signals - newser.com
Is TG Therapeutics Inc. reversing from oversold territoryMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
What indicators show strength in TG Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - newser.com
Analysts Offer Predictions for TG Therapeutics Q3 Earnings - MarketBeat
What analysts say about TG Therapeutics Inc stockEarnings Forecast Updates & Identify Breakout Stocks - earlytimes.in
TG Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
HC Wainwright Weighs in on TG Therapeutics FY2029 Earnings - MarketBeat
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption - MSN
Is TG Therapeutics Inc. forming a bottoming baseMarket Performance Report & Reliable Entry Point Alerts - newser.com
TGTX Receives 'Buy' Rating from HC Wainwright & Co. with $60 Pri - GuruFocus
Analyzing TG Therapeutics Inc. with risk reward ratio chartsQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Detecting support and resistance levels for TG Therapeutics Inc.July 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain - Yahoo Finance
What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders - Yahoo Finance
A Look at TG Therapeutics (TGTX) Valuation Following Positive Six-Year BRIUMVI Trial Results - Sahm
TG Therapeutics, Inc.'s (NASDAQ:TGTX) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 5.8% Over Last Week - 富途牛牛
Key metrics from TG Therapeutics Inc.’s quarterly dataTrade Volume Summary & Precise Buy Zone Identification - newser.com
Can TG Therapeutics Inc. stock rebound after recent weaknessBear Alert & Real-Time Stock Movement Alerts - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - Sahm
Is TG Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside - DirectorsTalk Interviews
TG Therapeutics, Inc. (TGTX) Investor Outlook: Riding On A 92.10% Revenue Growth Wave - DirectorsTalk Interviews
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
What drives TG Therapeutics Inc stock priceGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Is TG Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Demo Trading Rooms Open Daily - Early Times
TG Therapeutics (TGTX) Is Up 9.7% After Six-Year BRIUMVI MS Data Shows Sustained Efficacy and Safety - Sahm
Tg Therapeutics And Ke Holdings Top The Bull Strangle Watch List For This Week - Barchart.com
TG Therapeutics’ MS drug shows low relapse rate after six years - Investing.com Nigeria
TG Therapeutics’ MS drug shows low relapse rate after six years By Investing.com - Investing.com South Africa
TGTX Shares Rise on Promising Six-Year Data from ULTIMATE Trials - GuruFocus
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):